Conversely, rosiglitazone shows mixed effects, partially downregulating insulin signaling proteins (IR, IRS1 and AKT) in T2D [143], but enhancing insulin signaling ex vivo in PreDM rats [141]. Here, AKT1 is linked to type 2 diabetes mellitus.